 Nicholas Walter
Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium tuberculosis | 21 | 2026 | 316 | 6.480 |
Why?
| | Tuberculosis | 19 | 2026 | 279 | 5.920 |
Why?
| | Antitubercular Agents | 15 | 2026 | 200 | 4.340 |
Why?
| | Tuberculosis, Pulmonary | 9 | 2024 | 129 | 2.400 |
Why?
| | Diarylquinolines | 4 | 2025 | 14 | 1.440 |
Why?
| | RNA, Ribosomal | 2 | 2021 | 168 | 1.330 |
Why?
| | Sputum | 7 | 2021 | 311 | 1.320 |
Why?
| | Linezolid | 3 | 2025 | 23 | 1.210 |
Why?
| | RNA, Bacterial | 4 | 2025 | 189 | 1.140 |
Why?
| | Mice, Inbred BALB C | 6 | 2026 | 1271 | 0.880 |
Why?
| | Anti-Bacterial Agents | 2 | 2025 | 1865 | 0.700 |
Why?
| | RNA Precursors | 1 | 2021 | 156 | 0.630 |
Why?
| | Drug Therapy, Combination | 5 | 2025 | 1042 | 0.590 |
Why?
| | Transcriptome | 4 | 2025 | 1010 | 0.590 |
Why?
| | Polymerase Chain Reaction | 1 | 2022 | 1052 | 0.580 |
Why?
| | Tuberculosis, Multidrug-Resistant | 2 | 2025 | 50 | 0.580 |
Why?
| | Microbial Viability | 1 | 2018 | 91 | 0.550 |
Why?
| | Biomarkers | 5 | 2021 | 4179 | 0.550 |
Why?
| | Latent Tuberculosis | 3 | 2018 | 68 | 0.530 |
Why?
| | Disease Models, Animal | 6 | 2026 | 4413 | 0.500 |
Why?
| | Cell Membrane | 1 | 2018 | 723 | 0.440 |
Why?
| | Mice | 9 | 2026 | 18092 | 0.420 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2016 | 649 | 0.410 |
Why?
| | Energy Metabolism | 1 | 2018 | 930 | 0.370 |
Why?
| | Nitroimidazoles | 3 | 2025 | 13 | 0.350 |
Why?
| | Emigrants and Immigrants | 1 | 2014 | 149 | 0.340 |
Why?
| | Gene Expression Regulation, Bacterial | 3 | 2023 | 321 | 0.310 |
Why?
| | Microbial Sensitivity Tests | 3 | 2025 | 367 | 0.300 |
Why?
| | Animals | 9 | 2026 | 37642 | 0.300 |
Why?
| | Pyrazinamide | 2 | 2025 | 11 | 0.290 |
Why?
| | Rifampin | 2 | 2026 | 80 | 0.280 |
Why?
| | Wound Healing | 1 | 2010 | 350 | 0.270 |
Why?
| | Gene Expression Profiling | 3 | 2023 | 1769 | 0.270 |
Why?
| | Public Health | 1 | 2012 | 555 | 0.260 |
Why?
| | Communicable Disease Control | 1 | 2008 | 86 | 0.260 |
Why?
| | HIV Infections | 6 | 2020 | 2970 | 0.260 |
Why?
| | MicroRNAs | 1 | 2012 | 694 | 0.240 |
Why?
| | Anti-Infective Agents | 2 | 2023 | 240 | 0.240 |
Why?
| | Streptomycin | 1 | 2025 | 18 | 0.230 |
Why?
| | Ethambutol | 1 | 2025 | 25 | 0.220 |
Why?
| | Female | 14 | 2026 | 75727 | 0.220 |
Why?
| | Protein Kinases | 2 | 2017 | 308 | 0.220 |
Why?
| | Isoniazid | 1 | 2025 | 61 | 0.220 |
Why?
| | Drug Interactions | 1 | 2025 | 404 | 0.210 |
Why?
| | Transcription, Genetic | 2 | 2023 | 1493 | 0.210 |
Why?
| | Guideline Adherence | 1 | 2008 | 557 | 0.200 |
Why?
| | Mice, Inbred C3H | 1 | 2023 | 269 | 0.200 |
Why?
| | Mice, Inbred Strains | 1 | 2023 | 412 | 0.190 |
Why?
| | Wounds and Injuries | 1 | 2010 | 896 | 0.190 |
Why?
| | Genetic Predisposition to Disease | 1 | 2010 | 2373 | 0.180 |
Why?
| | Humans | 24 | 2025 | 141265 | 0.180 |
Why?
| | Coinfection | 3 | 2018 | 131 | 0.180 |
Why?
| | Adaptation, Physiological | 2 | 2023 | 563 | 0.180 |
Why?
| | Lung | 3 | 2024 | 4129 | 0.170 |
Why?
| | Ethanol | 1 | 2025 | 629 | 0.160 |
Why?
| | Bacterial Proteins | 2 | 2017 | 912 | 0.160 |
Why?
| | Uganda | 5 | 2020 | 86 | 0.160 |
Why?
| | Tuberculosis Vaccines | 1 | 2018 | 5 | 0.140 |
Why?
| | Phenotype | 2 | 2025 | 3177 | 0.140 |
Why?
| | Lung Neoplasms | 1 | 2010 | 2555 | 0.130 |
Why?
| | Specimen Handling | 2 | 2016 | 180 | 0.130 |
Why?
| | RNA | 2 | 2014 | 930 | 0.130 |
Why?
| | Recurrence | 2 | 2026 | 1108 | 0.130 |
Why?
| | AIDS-Related Opportunistic Infections | 2 | 2018 | 126 | 0.130 |
Why?
| | Adult | 8 | 2021 | 39201 | 0.130 |
Why?
| | DNA, Bacterial | 1 | 2018 | 333 | 0.120 |
Why?
| | Anti-Retroviral Agents | 1 | 2018 | 240 | 0.120 |
Why?
| | Genes, Bacterial | 1 | 2016 | 165 | 0.120 |
Why?
| | Microscopy | 2 | 2013 | 156 | 0.110 |
Why?
| | Philippines | 1 | 2014 | 51 | 0.110 |
Why?
| | Male | 9 | 2021 | 70061 | 0.100 |
Why?
| | ROC Curve | 1 | 2015 | 591 | 0.100 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2013 | 35 | 0.100 |
Why?
| | Antigens, Fungal | 1 | 2013 | 27 | 0.100 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 344 | 0.100 |
Why?
| | Cryptococcosis | 1 | 2013 | 31 | 0.100 |
Why?
| | Genome, Bacterial | 1 | 2014 | 151 | 0.100 |
Why?
| | Nystatin | 1 | 2012 | 1 | 0.100 |
Why?
| | Mice, Inbred C57BL | 1 | 2023 | 5901 | 0.100 |
Why?
| | Drug Monitoring | 1 | 2016 | 398 | 0.100 |
Why?
| | Chlorhexidine | 1 | 2012 | 24 | 0.090 |
Why?
| | DNA-Binding Proteins | 2 | 2017 | 1483 | 0.090 |
Why?
| | California | 1 | 2014 | 457 | 0.090 |
Why?
| | Oxidative Stress | 1 | 2018 | 1327 | 0.090 |
Why?
| | Drug Discovery | 1 | 2012 | 146 | 0.090 |
Why?
| | Treatment Failure | 1 | 2012 | 354 | 0.090 |
Why?
| | HIV | 1 | 2012 | 248 | 0.090 |
Why?
| | Treatment Outcome | 2 | 2025 | 11194 | 0.080 |
Why?
| | Pneumonia | 1 | 2015 | 656 | 0.080 |
Why?
| | Aged | 3 | 2015 | 24796 | 0.080 |
Why?
| | Middle Aged | 4 | 2018 | 34595 | 0.070 |
Why?
| | RNA, Messenger | 1 | 2016 | 2826 | 0.070 |
Why?
| | Neoplasm Metastasis | 1 | 2010 | 676 | 0.070 |
Why?
| | San Francisco | 1 | 2008 | 59 | 0.070 |
Why?
| | Young Adult | 2 | 2015 | 13665 | 0.070 |
Why?
| | Case-Control Studies | 1 | 2015 | 3580 | 0.070 |
Why?
| | Emigration and Immigration | 1 | 2008 | 56 | 0.070 |
Why?
| | Age Factors | 1 | 2014 | 3292 | 0.060 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2010 | 641 | 0.060 |
Why?
| | Inpatients | 2 | 2020 | 512 | 0.060 |
Why?
| | Levofloxacin | 1 | 2025 | 20 | 0.060 |
Why?
| | Clofazimine | 1 | 2025 | 15 | 0.060 |
Why?
| | Oxazoles | 1 | 2025 | 46 | 0.060 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2025 | 77 | 0.060 |
Why?
| | United States | 2 | 2015 | 15243 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 367 | 0.050 |
Why?
| | Aged, 80 and over | 1 | 2015 | 7947 | 0.050 |
Why?
| | Models, Biological | 1 | 2010 | 1826 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2010 | 2504 | 0.050 |
Why?
| | Drug Administration Schedule | 1 | 2025 | 773 | 0.050 |
Why?
| | Macrophages | 1 | 2010 | 1563 | 0.050 |
Why?
| | Sensitivity and Specificity | 2 | 2020 | 1974 | 0.050 |
Why?
| | Benchmarking | 1 | 2023 | 179 | 0.040 |
Why?
| | Inflammation | 1 | 2010 | 2895 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2025 | 1605 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2020 | 417 | 0.040 |
Why?
| | Gambia | 1 | 2017 | 8 | 0.030 |
Why?
| | Antigens, Bacterial | 1 | 2018 | 125 | 0.030 |
Why?
| | Antibodies, Bacterial | 1 | 2018 | 145 | 0.030 |
Why?
| | Ghana | 1 | 2017 | 38 | 0.030 |
Why?
| | Molecular Epidemiology | 1 | 2017 | 72 | 0.030 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2018 | 278 | 0.030 |
Why?
| | World Health Organization | 1 | 2016 | 103 | 0.030 |
Why?
| | Adolescent | 1 | 2015 | 22064 | 0.030 |
Why?
| | Prospective Studies | 2 | 2020 | 7787 | 0.030 |
Why?
| | Metabolome | 1 | 2018 | 366 | 0.030 |
Why?
| | Cryptococcus | 1 | 2013 | 15 | 0.020 |
Why?
| | Proteome | 1 | 2018 | 483 | 0.020 |
Why?
| | Africa | 1 | 2013 | 115 | 0.020 |
Why?
| | Standard of Care | 1 | 2013 | 77 | 0.020 |
Why?
| | Mouthwashes | 1 | 2012 | 12 | 0.020 |
Why?
| | HIV-1 | 1 | 2018 | 880 | 0.020 |
Why?
| | Diagnostic Tests, Routine | 1 | 2013 | 110 | 0.020 |
Why?
| | Colony Count, Microbial | 1 | 2012 | 123 | 0.020 |
Why?
| | Genotype | 1 | 2017 | 1865 | 0.020 |
Why?
| | CD4 Lymphocyte Count | 1 | 2012 | 273 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2012 | 290 | 0.020 |
Why?
| | Oxygen | 1 | 2017 | 992 | 0.020 |
Why?
| | Survival Rate | 1 | 2016 | 1973 | 0.020 |
Why?
| | Cough | 1 | 2012 | 133 | 0.020 |
Why?
| | Mortality | 1 | 2013 | 360 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2017 | 2132 | 0.020 |
Why?
| | Prevalence | 1 | 2016 | 2793 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2020 | 5651 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3515 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1543 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2016 | 2905 | 0.020 |
Why?
| | Incidence | 1 | 2013 | 2800 | 0.020 |
Why?
| | Time Factors | 1 | 2012 | 6971 | 0.010 |
Why?
|
|
Walter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|